Compounds > verapamil
Page last updated: 2024-10-24

verapamil and Kidney Failure, Chronic

verapamil has been researched along with Kidney Failure, Chronic in 77 studies

Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.

Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.

Research Excerpts

ExcerptRelevanceReference
"Renal failure patients with baseline mild hyperkalaemia are particularly liable to bradyarrhythmias with SR verapamil."7.78Junctional bradycardia with verapamil in renal failure--care required even with mild hyperkalaemia. ( Al-Mutairi, S; Aldabie, G; El Sayed, A; Hegazi, MO, 2012)
"SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism."4.81[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002)
"Renal failure patients with baseline mild hyperkalaemia are particularly liable to bradyarrhythmias with SR verapamil."3.78Junctional bradycardia with verapamil in renal failure--care required even with mild hyperkalaemia. ( Al-Mutairi, S; Aldabie, G; El Sayed, A; Hegazi, MO, 2012)
"The calcium antagonist verapamil has been demonstrated to be effective in reducing hypertension in patients in whom sodium intake was not restricted."3.68The antihypertensive effect of verapamil in patients with chronic renal failure. ( Alcazar, JM; Rodicio, JL; Ruilope, LM, 1992)
"Microalbuminuria is an early marker of diabetic nephropathy, and its prevention can be considered to be the primary prevention of diabetic nephropathy."2.69Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial. ( Remuzzi, G; Ruggenenti, P, 1998)
" The terminal elimination rate constant, clearance, volume of distribution, and bioavailability of verapamil were not significantly different between the two groups of subjects."2.67The pharmacokinetics of racemic verapamil in patients with impaired renal function. ( Frantz, RP; Kurtz, SB; McCarthy, JT; Moyer, TP; Smith, RL; Theobald, HM; Zachariah, PK, 1991)
" The efficacy of MMF as an immunosuppressant and long-term safety in cats of this dosage regimen is unknown."2.61 ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019)
" In spite of the low dose ingested, the postmortem cardiac blood verapamil level was clearly toxic (6000 ng/mL, or 6 mg/L)."2.44Verapamil toxicity: an unusual case report and review of the literature. ( Batalis, NI; Harley, RA; Schandl, CA, 2007)
"Although end-stage renal disease (ESRD) currently affects only a small percentage (<0."2.42Calcium channel blockers and the kidney. ( Sica, D, 2004)
"Three hypertensive patients with chronic renal failure treated with slow-release verapamil at the recommended doses for high blood pressure experienced acute deleterious effects shortly after treatment (6 h to 3 days)."2.39Verapamil deleterious effects in chronic renal failure. ( Alegría, E; Errasti, P; Huelmos, A; Purroy, A; Váquez, C, 1996)
" In experimental chronic renal failure, the long-term administration of verapamil protects against renal dysfunction and damage, independent of any effect on systemic mean arterial pressure."2.38Role of calcium channel blockers in protection against experimental renal injury. ( Schrier, RW, 1991)
" These products are well absorbed from the gastrointestinal tract but undergo variable degrees of transformation during the first passage through the liver."2.37[Clinical pharmacology of calcium inhibitors]. ( Martre, H; Singlas, E; Taburet, AM, 1985)
"Studies demonstrated that chronic renal failure (CRF) affects the expression and activity of intestinal, hepatic, and renal drug transporters."1.38Effects of chronic renal failure on brain drug transporters in rats. ( Beauchemin, S; Laurin, LP; Leblond, FA; Michaud, J; Naud, J; Pichette, V, 2012)
"Verapamil treatment seems to ameliorate the renal effects of exercise on GFR in these patients, and this may in part be mediated via a stimulatory effect on ANP."1.31Effect of light exercise on renal hemodynamics in patients with hypertension and chronic renal disease. ( Iversen, BM; Myking, O; Ofstad, J; Svarstad, E, 2002)
"It was reduced in rats with chronic renal failure, reflecting reduced intestinal drug elimination via a decrease in P-glycoprotein transport activity rather than via protein underexpression."1.31Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion. ( Auchère, D; Banide, H; Farinotti, R; Lacour, B; Leroy, C; Tardivel, S; Veau, C, 2001)
"Hypertriglyceridemia is common in chronic renal failure (CRF); this derangement is due to decreased peripheral removal of triglycerides."1.29Verapamil prevents chronic renal failure-induced abnormalities in lipid metabolism. ( Akmal, M; Kasim, SE; Massry, SG; Oh, HY; Perkins, S; Smogorzewski, M, 1993)
"Patients with chronic renal failure (CRF) display impaired phagocytosis by the polymorphonuclear leucocytes (PMNL), and these cells have elevated basal levels of cytosolic calcium ([Ca2+]i) and reduced ATP content."1.28Impaired phagocytosis in chronic renal failure is mediated by secondary hyperparathyroidism. ( Alexiewicz, JM; Chervu, I; Fadda, GZ; Kiersztejn, M; Massry, SG; Smogorzewski, M, 1992)
"It has been suggested that excess parathyroid hormone (PTH) in chronic renal failure (CRF) or chronic administration of PTH to normal rats caused derangements in norepinephrine and phospholipid metabolism of brain synaptosomes, because of an increase in their resting levels of cytosolic calcium which may induce a decrease in synaptosomal content of ATP."1.28Chronic parathyroid hormone excess in vivo increases resting levels of cytosolic calcium in brain synaptosomes: studies in the presence and absence of chronic renal failure. ( Fadda, GZ; Koureta, P; Massry, SG; Perna, AF; Smogorzewski, M, 1991)
"Four hypertensive patients with chronic renal insufficiency or end-stage renal disease who were treated with sustained-release verapamil hydrochloride subsequently developed acute toxic effects."1.28Acute toxic effects of sustained-release verapamil in chronic renal failure. ( Bierman, MH; Hammeke, MD; Pritza, DR, 1991)
"Verapamil treatment of normal rats for 21 days did not affect synaptosomal content of calcium or phospholipids."1.28Effect of verapamil on CRF-induced abnormalities in phospholipid contents of brain synaptosomes. ( Islam, A; Massry, SG; Smogorzewski, M, 1990)
"Verapamil treatment of normal rats for 21 days did not affect synaptosomal NE content, release, or uptake, Na(+)-K(+)-ATPase activity, or calcium content."1.28Verapamil corrects abnormalities in norepinephrine metabolism of brain synaptosomes in CRF. ( Islam, A; Massry, SG; Minasian, R; Smogorzewski, M; Soliman, AR, 1990)
" The patients were continuously treated with verapamil for two periods of two weeks at two dosage levels, 120 mg/d and 240 mg/d, whereafter verapamil was withdrawn."1.28Verapamil-digoxin interaction in chronic hemodialysis patients. ( Halck, S; Johannessen, AC; Klitgaard, NA; Rendtorff, C, 1990)
"Verapamil was found to diminish depression of neutrophil chemiluminescence both at rest and following activation with opsonized zymosan."1.28Effect of verapamil on chemiluminescence of peripheral blood neutrophils during hemodialysis in chronic uremic patients. ( Kantorski, J; Luciak, M; Pawlicki, L; Pokoca, L; Tchórzewski, H; Trznadel, K, 1989)
"Enalapril treatment (5 mg/kg/day, n = 11) or felodipine (30 mg/kg/day, n = 11) reduced systolic blood pressure to a comparable degree."1.27Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat. ( Cubela, R; Debrevi, L; Jackson, B; Johnston, CI; Whitty, M, 1987)
" In conclusion, independent of any effect on systematic MAP, chronic administration of Ver protects against renal dysfunction, histological damage, nephrocalcinosis and myocardial calcification, and improves survival in the remnant model of chronic renal disease."1.27Verapamil protects against progression of experimental chronic renal failure. ( Burke, TJ; Hammond, WS; Harris, DC; Schrier, RW, 1987)
" injection, the terminal phase half-life and total plasma clearance of verapamil in both groups were similar."1.27Pharmacokinetics of verapamil in patients with renal failure. ( Mooy, J; Muytjens, A; Rahn, KH; Schols, M; v Baak, M; v Hooff, M, 1985)

Research

Studies (77)

TimeframeStudies, this research(%)All Research%
pre-199022 (28.57)18.7374
1990's42 (54.55)18.2507
2000's8 (10.39)29.6817
2010's5 (6.49)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Naud, J1
Laurin, LP1
Michaud, J1
Beauchemin, S1
Leblond, FA1
Pichette, V1
Bobenko, AI1
Heller, S1
Schmitt, N1
Cherdtrakulkiat, R1
Lawung, R1
Nabu, S1
Tantimavanich, S1
Sinthupoom, N1
Prachayasittikul, S1
Prachayasittikul, V1
Zhang, B1
Wu, C1
Zhang, Z2
Yan, K1
Li, C2
Li, Y4
Li, L3
Zheng, C1
Xiao, Y1
He, D1
Zhao, F1
Su, JF1
Lun, SM1
Hou, YJ1
Duan, LJ1
Wang, NC1
Shen, FF1
Zhang, YW1
Gao, ZW1
Li, J5
Du, XJ1
Zhou, FY1
Yin, Z1
Zhu, J2
Yan, D1
Lou, H1
Yu, H1
Feng, C1
Wang, Z1
Wang, Y4
Hu, X1
Li, Z2
Shen, Y1
Hu, D1
Chen, H1
Wu, X1
Duan, Y1
Zhi, D1
Zou, M2
Zhao, Z1
Zhang, X2
Yang, X2
Zhang, J2
Wang, H1
Popović, KJ1
Popović, DJ1
Miljković, D1
Lalošević, D1
Čapo, I1
Popović, JK1
Liu, M1
Song, H2
Xing, Z1
Lu, G1
Chen, D1
Valentini, AM1
Di Pinto, F1
Coletta, S1
Guerra, V1
Armentano, R1
Caruso, ML1
Gong, J1
Wang, N1
Bian, L1
Wang, M1
Ye, M1
Wen, N1
Fu, M1
Fan, W1
Meng, Y1
Dong, G1
Lin, XH1
Liu, HH1
Gao, DM1
Cui, JF1
Ren, ZG1
Chen, RX1
Önal, B1
Özen, D1
Demir, B1
Akkan, AG1
Özyazgan, S1
Payette, G1
Geoffroy, V1
Martineau, C1
Villemur, R1
Jameel, T1
Baig, M1
Gazzaz, ZJ1
Tashkandi, JM1
Al Alhareth, NS1
Khan, SA1
Butt, NS1
Wang, J2
Geng, Y1
Zhang, Y3
Wang, X2
Liu, J2
Basit, A1
Miao, T1
Liu, W1
Jiang, W1
Yu, ZY1
Wu, L2
Qu, B1
Sun, JX1
Cai, AL1
Xie, LM1
Groeneveld, J1
Ho, SL1
Mackensen, A1
Mohtadi, M1
Laepple, T1
Genovesi, S1
Nava, E1
Bartolucci, C1
Severi, S1
Vincenti, A1
Contaldo, G1
Bigatti, G1
Ciurlino, D1
Bertoli, SV1
Slovak, JE1
Hwang, JK1
Rivera, SM1
Villarino, NF1
Li, S1
Cao, G1
Ling, M1
Ji, J1
Zhao, D1
Sha, Y1
Gao, X1
Liang, C2
Guo, Q1
Zhou, C1
Ma, Z1
Xu, J1
Wang, C1
Zhao, W1
Xia, X1
Jiang, Y1
Peng, J1
Jia, Z1
Li, F1
Chen, X2
Mo, J1
Zhang, S2
Li, X1
Huang, T1
Zhu, Q1
Wang, S1
Ge, RS1
Fortunato, G1
Lin, J2
Agarwal, PK1
Kohen, A1
Singh, P1
Cheatum, CM1
Zhu, D1
Hayman, A1
Kebede, B1
Stewart, I1
Chen, G1
Frew, R1
Guo, X1
Gong, Q1
Borowiec, J1
Han, S1
Zhang, M1
Willis, M1
Kreouzis, T1
Yu, K1
Chirvony, VS1
Sekerbayev, KS1
Pérez-Del-Rey, D1
Martínez-Pastor, JP1
Palazon, F1
Boix, PP1
Taurbayev, TI1
Sessolo, M1
Bolink, HJ1
Lu, M1
Lan, Y1
Xiao, J1
Song, M1
Chen, C1
Huang, Q1
Cao, Y1
Ho, CT1
Qi, B1
Wang, Q1
Zhang, W1
Fang, L1
Xie, CL1
Chen, R1
Yang, S1
Xia, JM1
Zhang, GY1
Chen, CH1
Yang, XW1
Domenech-Ximenos, B1
Garza, MS1
Prat-González, S1
Sepúlveda-Martínez, Á1
Crispi, F1
Perea, RJ1
Garcia-Alvarez, A1
Sitges, M1
Kalumpha, M1
Guyo, U1
Zinyama, NP1
Vakira, FM1
Nyamunda, BC1
Varga, M1
Drácz, L1
Kolbenheyer, E1
Varga, F1
Patai, ÁV1
Solymosi, N1
Patai, Á1
Kiss, J1
Gaál, V1
Nyul, Z1
Mosdósi, B1
Valdez, M1
Moosavi, L1
Heidari, A1
Novakovic-Agopian, T1
Kornblith, E1
Abrams, G1
McQuaid, JR1
Posecion, L1
Burciaga, J1
D'Esposito, M1
Chen, AJW1
Samy El Gendy, NM1
Wesolowska, P1
Georg, D1
Lechner, W1
Kazantsev, P1
Bokulic, T1
Tedgren, AC1
Adolfsson, E1
Campos, AM1
Alves, VGL1
Suming, L1
Hao, W1
Ekendahl, D1
Koniarova, I1
Bulski, W1
Chelminski, K1
Samper, JLA1
Vinatha, SP1
Rakshit, S1
Siri, S1
Tomsejm, M1
Tenhunen, M1
Povall, J1
Kry, SF1
Followill, DS1
Thwaites, DI1
Izewska, J1
Kang, JH1
Yoon, Y1
Song, J1
Van de Winckel, A1
Gauthier, L1
Chao, CT1
Lee, YH1
Li, CM1
Han, DS1
Huang, JW1
Huang, KC1
Ni, L1
Güttinger, R1
Triana, CA1
Spingler, B1
Baldridge, KK1
Patzke, GR1
Shen, X1
Wang, B1
Xie, S1
Deng, W1
Wu, D1
Zhang, Q1
Voskamp, BJ1
Peelen, MJCS1
Ravelli, ACJ1
van der Lee, R1
Mol, BWJ1
Pajkrt, E1
Ganzevoort, W1
Kazemier, BM1
Tibrewala, R1
Bahroos, E1
Mehrabian, H1
Foreman, SC1
Link, TM1
Pedoia, V1
Majumdar, S1
Jablonski, CL1
Leonard, C1
Salo, P1
Krawetz, RJ1
Yoon, N1
Hong, SN1
Cho, JG1
Jeong, HK1
Lee, KH1
Park, HW1
Barman, S1
Konai, MM1
Samaddar, S1
Haldar, J1
Mohamed, HSH1
Li, CF1
Hu, ZY1
Deng, Z1
Chen, LH1
Su, BL1
Chu, K1
Liu, YP1
Li, YB1
Zhang, H1
Xu, C1
Zou, Z1
Wu, Z1
Xia, Y1
Zhao, P1
Wang, HT1
de Biase, S1
Pellitteri, G1
Gigli, GL1
Valente, M1
Benhenda, N1
Bernard-Brunet, A1
Ferrandière, M1
Salamé, E1
Babuty, D1
Pirker, S1
Baumgartner, C1
Hegazi, MO1
Aldabie, G1
Al-Mutairi, S1
El Sayed, A1
Bernadet-Monrozies, P1
Rostaing, L1
Kamar, N1
Durand, D1
Svarstad, E1
Myking, O1
Ofstad, J1
Iversen, BM1
Sica, D1
Letavernier, E1
Couzi, L1
Delmas, Y1
Moreau, K1
Murcott, O1
de Précigout, V1
Batalis, NI1
Harley, RA1
Schandl, CA1
Keefe, DL1
Yee, YG1
Kates, RE1
Schohn, DC1
Jahn, HA1
Maareck, M1
Klin, M2
Smogorzewski, M19
Massry, SG24
Ni, Z4
Suzuki, H1
Schaefer, L1
Ling, H1
Schaefer, RM1
Dämmrich, J1
Teschner, M1
Heidland, A1
Tian, J3
Huelmos, A2
Alegría, E2
Vázquez, C1
Oh, HY2
Fadda, GZ9
Liou, HH1
Zhang, YB1
Kedes, L2
Patel, R1
Lipper, B1
Schwartzbard, A1
Nelson, C1
O'Connor, MA1
Frishman, W1
Schohn, D1
Maarek, M1
Jahn, H1
Tomás, S1
Duaso, E1
Llibre, J1
Akmal, M3
Perkins, S1
Kasim, SE1
August, P1
Lenz, T1
Laragh, JH1
Váquez, C1
Errasti, P1
Purroy, A1
Gonsorcík, J1
Szakács, M1
Palko, S1
Mydlík, M1
Bitar, R1
Martín, B1
López-Novoa, JM1
Macías-Nuñez, JF1
Michnowska, M1
Nand, N1
Agarwal, HK1
Mahajan, SK1
Thukral, S1
Sharma, M1
Kumar, P1
Pitt, B1
Ruggenenti, P1
Remuzzi, G1
Martínez-Castelao, A1
Hueso, M1
Sanz, V1
Rejas, J1
Alsina, J1
Grinyó, JM1
Martín-Gago, J1
Pascual, J1
Rodríguez-Palomares, JR1
Marc n, R1
Teruel, JL1
Liaño, F1
Ortuño, J1
Veau, C1
Leroy, C1
Banide, H1
Auchère, D1
Tardivel, S1
Farinotti, R1
Lacour, B1
Smogorzewski, MJ1
Faller, J1
Hess, B1
Hepp, A1
Maisch, B1
Raff, U1
Hayduk, K1
Ruilope, LM2
Casal, MC1
Guerrero, L1
Alcázar, JM2
Férnandez, ML1
Lahera, V1
Rodicio, JL2
Thanakitcharu, P3
Hajjar, SM3
Levi, E1
Stojceva-Taneva, O1
Kiersztejn, M2
Chervu, I1
Alexiewicz, JM1
Koureta, P2
Perna, AF3
Zayed, MA1
Pritza, DR1
Bierman, MH1
Hammeke, MD1
Schrier, RW3
Zachariah, PK1
Moyer, TP1
Theobald, HM1
Frantz, RP1
Kurtz, SB1
McCarthy, JT1
Smith, RL1
Luquita, MG1
Weinschelbaum-Jairala, S1
Islam, A2
Minasian, R1
Soliman, AR3
Rendtorff, C1
Johannessen, AC1
Halck, S1
Klitgaard, NA1
Jackson, B1
Cubela, R1
Debrevi, L1
Whitty, M1
Johnston, CI1
Whelton, PK1
Watson, AJ1
Kone, B1
Fortuin, NJ1
Lipson, LG1
Vargemezis, V1
Pasadakis, P1
Thodis, E1
Pawlicki, L1
Tchórzewski, H1
Trznadel, K1
Luciak, M1
Kantorski, J1
Pokoca, L1
Chagnac, A1
Gazit, D1
Zahavi, I1
Sela, J1
Levi, J1
Yoshioka, T1
Shiraga, H1
Yoshida, Y1
Fogo, A1
Glick, AD1
Deen, WM1
Hoyer, JR1
Ichikawa, I1
Hanyok, JJ1
Chow, MS1
Kluger, J1
Izard, MW1
Robson, RA1
Fraenkel, M1
Barratt, LJ1
Birkett, DJ1
Harris, DC2
Chan, L1
Rahn, KH2
van Bortel, LM1
Mooy, JM1
Hammond, WS1
Burke, TJ1
Goligorsky, MS1
Chaimovitz, C1
Shany, S1
Rapoport, J1
Sharony, Y1
Haichenco, J1
Singlas, E1
Martre, H1
Taburet, AM1
Mooy, J1
Schols, M1
v Baak, M1
v Hooff, M1
Muytjens, A1
Shah, GM1
Winer, RL1
Bender, F1
Reploh, HD1

Reviews

10 reviews available for verapamil and Kidney Failure, Chronic

ArticleYear
    Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227

    Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P

2019
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Presse medicale (Paris, France : 1983), 2002, Nov-09, Volume: 31, Issue:36

    Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito

2002
Calcium channel blockers and the kidney.
    Clinical cornerstone, 2004, Volume: 6, Issue:4

    Topics: Black or African American; Calcium Channel Blockers; Diabetic Nephropathies; Dihydropyridines; Dilti

2004
Verapamil toxicity: an unusual case report and review of the literature.
    The American journal of forensic medicine and pathology, 2007, Volume: 28, Issue:2

    Topics: Accidents; Antihypertensive Agents; Calcium Channel Blockers; Drug Combinations; Drug Overdose; Fema

2007
[The toxicity of slow-release verapamil and chronic kidney disease].
    Revista espanola de cardiologia, 1994, Volume: 47, Issue:11

    Topics: Aged; Delayed-Action Preparations; Drug Overdose; Female; Humans; Hypertension; Kidney Failure, Chro

1994
Verapamil deleterious effects in chronic renal failure.
    Nephron, 1996, Volume: 72, Issue:3

    Topics: Aged; Bradycardia; Delayed-Action Preparations; Electrocardiography; Female; Heart Rate; Humans; Kid

1996
Diversity of calcium antagonists.
    Clinical therapeutics, 1997, Volume: 19 Suppl A

    Topics: Angina Pectoris; Arteriosclerosis; Benzimidazoles; Calcium Channel Blockers; Diltiazem; Humans; Hype

1997
Central nervous dysfunction in uremia.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2001, Volume: 38, Issue:4 Suppl 1

    Topics: Adenosine Triphosphate; Animals; Atrophy; Brain; Brain Diseases; Calcium; Cytosol; Humans; Kidney Fa

2001
Role of calcium channel blockers in protection against experimental renal injury.
    The American journal of medicine, 1991, May-17, Volume: 90, Issue:5A

    Topics: Acute Kidney Injury; Animals; Calcium; Disease Models, Animal; Dogs; Glomerular Filtration Rate; Hum

1991
[Clinical pharmacology of calcium inhibitors].
    Archives des maladies du coeur et des vaisseaux, 1985, Volume: 78 Spec No

    Topics: Age Factors; Animals; Bepridil; Biological Availability; Biotransformation; Calcium Channel Blockers

1985

Trials

7 trials available for verapamil and Kidney Failure, Chronic

ArticleYear
Long term effects of sustained release verapamil on the renal and systemic haemodynamic parameters in hypertensive patients with mild to severe chronic renal failure.
    Drugs, 1993, Volume: 46 Suppl 2

    Topics: Delayed-Action Preparations; Electrolytes; Female; Heart Function Tests; Hemodynamics; Hormones; Hum

1993
[Effects of sustained-release verapamil on hemodynamics and renal function of patients with moderate to severe chronic renal failure].
    Presse medicale (Paris, France : 1983), 1993, Nov-27, Volume: 22, Issue:37

    Topics: Adult; Aged; Delayed-Action Preparations; Female; Glomerular Filtration Rate; Hemodynamics; Humans;

1993
Evaluation of efficacy of standard haemodialysis and verapamil added peritoneal dialysis.
    Indian journal of medical sciences, 1997, Volume: 51, Issue:3

    Topics: Adult; Chi-Square Distribution; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Peritone

1997
Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1998, Volume: 16, Issue:1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Diabete

1998
Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin.
    Kidney international. Supplement, 1998, Volume: 68

    Topics: Adult; Antihypertensive Agents; Calcium Channel Blockers; Doxazosin; Enalapril; Female; Follow-Up St

1998
Sodium intake does not influence the effect of verapamil in hypertensive patients with mild renal insufficiency.
    Drugs, 1992, Volume: 44 Suppl 1

    Topics: Blood Pressure; Delayed-Action Preparations; Humans; Hypertension; Kidney; Kidney Failure, Chronic;

1992
The pharmacokinetics of racemic verapamil in patients with impaired renal function.
    Journal of clinical pharmacology, 1991, Volume: 31, Issue:1

    Topics: Administration, Oral; Adult; Chromatography, High Pressure Liquid; Humans; Infusions, Intravenous; K

1991

Other Studies

60 other studies available for verapamil and Kidney Failure, Chronic

ArticleYear
Effects of chronic renal failure on brain drug transporters in rats.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:1

    Topics: Animals; Biological Transport, Active; Blood-Brain Barrier; Brain; Cells, Cultured; Kidney Failure,

2012
Fatal short-coupled torsade de pointes in a patient with primary oxalosis.
    Intensive care medicine, 2013, Volume: 39, Issue:10

    Topics: Anti-Arrhythmia Agents; Cardiomegaly; Defibrillators; Echocardiography; Fatal Outcome; Humans; Hyper

2013
Termination of refractory focal status epilepticus by the P-glycoprotein inhibitor verapamil.
    European journal of neurology, 2011, Volume: 18, Issue:12

    Topics: Aged, 80 and over; Anticonvulsants; Aspirin; ATP Binding Cassette Transporter, Subfamily B, Member 1

2011
Junctional bradycardia with verapamil in renal failure--care required even with mild hyperkalaemia.
    Journal of clinical pharmacy and therapeutics, 2012, Volume: 37, Issue:6

    Topics: Aged; Bradycardia; Calcium Channel Blockers; Delayed-Action Preparations; Female; Humans; Hyperkalem

2012
Effect of light exercise on renal hemodynamics in patients with hypertension and chronic renal disease.
    Scandinavian journal of urology and nephrology, 2002, Volume: 36, Issue:6

    Topics: Adult; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Captopril; Enalapril; Exe

2002
Verapamil and mild hyperkalemia in hemodialysis patients: a potentially hazardous association.
    Hemodialysis international. International Symposium on Home Hemodialysis, 2006, Volume: 10, Issue:2

    Topics: Blood Chemical Analysis; Follow-Up Studies; Heart Block; Humans; Hyperkalemia; Kidney Failure, Chron

2006
Verapamil protein binding in patients and in normal subjects.
    Clinical pharmacology and therapeutics, 1981, Volume: 29, Issue:1

    Topics: Adult; Aged; Animals; Blood Proteins; Cardiac Catheterization; Coronary Artery Bypass; Dogs; Heart D

1981
Chronic renal failure increases cytosolic Ca2+ of hepatocytes.
    The American journal of physiology, 1995, Volume: 269, Issue:1 Pt 1

    Topics: Adenosine Triphosphate; Animals; Calcium; Calcium-Transporting ATPases; Carrier Proteins; Cytosol; K

1995
Elevated cytosolic calcium of adipocytes in chronic renal failure.
    Kidney international, 1995, Volume: 47, Issue:6

    Topics: Adenosine Triphosphate; Adipocytes; Animals; Calcium; Calcium-Transporting ATPases; Cytosol; Kidney

1995
Prevention of cardiac hypertrophy in experimental chronic renal failure by long-term ACE inhibitor administration: potential role of lysosomal proteinases.
    American journal of nephrology, 1995, Volume: 15, Issue:2

    Topics: Animals; Cathepsin B; Cathepsin H; Cathepsin L; Cathepsins; Cysteine Endopeptidases; Enalapril; Endo

1995
Down-regulation of PTH-PTHrP receptor of heart in CRF: role of [Ca2+]i.
    Kidney international, 1995, Volume: 47, Issue:4

    Topics: Actins; Analysis of Variance; Animals; Blotting, Northern; Calcium; Down-Regulation; Kidney Failure,

1995
Abnormal leucine-induced insulin secretion in chronic renal failure.
    The American journal of physiology, 1994, Volume: 267, Issue:5 Pt 2

    Topics: Animals; Body Weight; Bridged Bicyclo Compounds; Creatinine; Glutamate Dehydrogenase; Glutaminase; I

1994
Altered cytosolic calcium homeostasis in rat cardiac myocytes in CRF.
    Kidney international, 1994, Volume: 45, Issue:4

    Topics: Adenosine Triphosphate; Animals; Calcium; Calcium-Transporting ATPases; Carrier Proteins; Cytosol; H

1994
PTH-PTHrP receptor mRNA is downregulated in chronic renal failure.
    American journal of nephrology, 1994, Volume: 14, Issue:1

    Topics: Animals; Blotting, Northern; Calcium; Down-Regulation; Kidney; Kidney Failure, Chronic; Liver; Parat

1994
Toxic effects of diltiazem in a patient with chronic renal failure.
    Journal of clinical pharmacology, 1994, Volume: 34, Issue:3

    Topics: Acidosis; Adult; Diltiazem; Heart Failure; Humans; Hyperkalemia; Hypotension; Kidney Failure, Chroni

1994
[Toxic effects of verapamil in chronic renal failure].
    Medicina clinica, 1994, Apr-02, Volume: 102, Issue:12

    Topics: Aged; Female; Humans; Hypertension; Kidney Failure, Chronic; Verapamil

1994
Derangements in acetylcholine metabolism in brain synaptosomes in chronic renal failure.
    Kidney international, 1993, Volume: 44, Issue:3

    Topics: Acetylcholine; Animals; Biological Transport, Active; Brain; Calcium; Choline; Choline Kinase; Kidne

1993
Verapamil prevents chronic renal failure-induced abnormalities in lipid metabolism.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1993, Volume: 22, Issue:1

    Topics: Animals; Calcium; Hypertriglyceridemia; Kidney Failure, Chronic; Lipase; Lipoprotein Lipase; Liver;

1993
Comparative renal hemodynamic effects of lisinopril, verapamil, and amlodipine in patients with chronic renal failure.
    American journal of hypertension, 1993, Volume: 6, Issue:4

    Topics: Amlodipine; Antihypertensive Agents; Dipeptides; Hemodynamics; Humans; Kidney Failure, Chronic; Lisi

1993
Impaired agonist-induced calcium signaling in hepatocytes from chronic renal failure rats.
    Kidney international, 1995, Volume: 48, Issue:4

    Topics: Animals; Calcium; Calcium Channel Blockers; Hormones; In Vitro Techniques; Kidney Failure, Chronic;

1995
[Pharmacotherapy of silent myocardial ischemia in patients on hemodialysis].
    Vnitrni lekarstvi, 1996, Volume: 42, Issue:12

    Topics: Adrenergic beta-Agonists; Adult; Aged; Calcium Channel Blockers; Female; Humans; Kidney Failure, Chr

1996
Reduction of renal function by angiotensin-converting enzyme inhibitors: effect of verapamil.
    Nephron, 1997, Volume: 75, Issue:4

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Drug Therapy, Combination;

1997
Impaired Na(+)-H+ exchanger activity of hepatocytes in chronic renal failure.
    Journal of the American Society of Nephrology : JASN, 1997, Volume: 8, Issue:6

    Topics: Animals; Calcium Channel Blockers; Kidney Failure, Chronic; Liver; Parathyroid Hormone; Parathyroide

1997
Complete atrioventricular blockade secondary to conventional-release verapamil in a patient on hemodialysis.
    Nephron, 1999, Volume: 83, Issue:1

    Topics: Aged; Female; Heart Block; Humans; Kidney Failure, Chronic; Renal Dialysis; Verapamil

1999
Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16, Issue:8

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily

2001
[Medicamentous kidney protection in type 2 diabetic patients--is cheaper also more economical? A model calculation for Swiss health care].
    Praxis, 2002, May-08, Volume: 91, Issue:19

    Topics: Adult; Antihypertensive Agents; Atenolol; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus, Ty

2002
[Comparative studies with propranolol, verapamil and atenolol in hypertensive dialysis patients].
    Verhandlungen der Deutschen Gesellschaft fur Kreislaufforschung, 1977, Volume: 43

    Topics: Atenolol; Humans; Hypertension, Renal; Kidney Failure, Chronic; Propanolamines; Propranolol; Renal D

1977
The antihypertensive effect of verapamil in patients with chronic renal failure.
    Journal of human hypertension, 1992, Volume: 6 Suppl 2

    Topics: Antihypertensive Agents; Diet, Sodium-Restricted; Dietary Proteins; Humans; Hypertension; Kidney Fai

1992
Verapamil reverses glucose intolerance in preexisting chronic renal failure: studies on mechanisms.
    American journal of nephrology, 1992, Volume: 12, Issue:3

    Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Blood Glucose; Calcium-Transporting ATPases;

1992
Decreased O2 consumption by PMNL from humans and rats with CRF: role of secondary hyperparathyroidism.
    Kidney international, 1992, Volume: 42, Issue:3

    Topics: Adult; Animals; Calcium; Female; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Male; Middle

1992
Impaired phagocytosis in chronic renal failure is mediated by secondary hyperparathyroidism.
    Kidney international, 1992, Volume: 41, Issue:6

    Topics: Animals; Calcium; Hyperparathyroidism, Secondary; In Vitro Techniques; Kidney Failure, Chronic; Male

1992
Impaired glucose-induced calcium signal in pancreatic islets in chronic renal failure.
    American journal of nephrology, 1991, Volume: 11, Issue:6

    Topics: Animals; Calcium; Calcium Channels; Glucose; Insulin; Insulin Secretion; Islets of Langerhans; Kidne

1991
Chronic parathyroid hormone excess in vivo increases resting levels of cytosolic calcium in brain synaptosomes: studies in the presence and absence of chronic renal failure.
    Journal of the American Society of Nephrology : JASN, 1991, Volume: 1, Issue:10

    Topics: Adenosine Triphosphate; Animals; Brain; Calcium; Cytosol; Kidney Failure, Chronic; Male; Parathyroid

1991
Effect of potassium chloride on cytosolic calcium of brain synaptosomes of rats with chronic renal failure.
    Mineral and electrolyte metabolism, 1991, Volume: 17, Issue:3

    Topics: Animals; Brain; Calcium; Creatinine; Cytosol; Kidney Failure, Chronic; Male; Norepinephrine; Parathy

1991
Verapamil prevents the metabolic and functional derangements in pancreatic islets of chronic renal failure rats.
    Endocrinology, 1991, Volume: 129, Issue:4

    Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Calcium-Transporting ATPases; Glucose; Insul

1991
Effect of chronic renal failure on Ca2+ ATPase of brain synaptosomes.
    Journal of the American Society of Nephrology : JASN, 1991, Volume: 2, Issue:6

    Topics: Animals; Brain; Ca(2+) Mg(2+)-ATPase; Calcium; Calcium-Transporting ATPases; Hyperparathyroidism, Se

1991
Acute toxic effects of sustained-release verapamil in chronic renal failure.
    Archives of internal medicine, 1991, Volume: 151, Issue:10

    Topics: Delayed-Action Preparations; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Age

1991
[Effect of verapamil on renal function in rats undergoing partial ablation of the kidney mass].
    Medicina, 1990, Volume: 50, Issue:4

    Topics: Animals; Creatinine; Kidney; Kidney Failure, Chronic; Male; Nephrectomy; Rats; Rats, Inbred Strains;

1990
Effect of verapamil on CRF-induced abnormalities in phospholipid contents of brain synaptosomes.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1990, Volume: 194, Issue:1

    Topics: Animals; Brain Chemistry; Calcium; Kidney Failure, Chronic; Male; Phospholipids; Rats; Rats, Inbred

1990
Verapamil corrects abnormalities in norepinephrine metabolism of brain synaptosomes in CRF.
    The American journal of physiology, 1990, Volume: 258, Issue:4 Pt 2

    Topics: Animals; Brain; Calcium; Kidney Failure, Chronic; Male; Norepinephrine; Rats; Rats, Inbred Strains;

1990
Verapamil-digoxin interaction in chronic hemodialysis patients.
    Scandinavian journal of urology and nephrology, 1990, Volume: 24, Issue:2

    Topics: Adult; Digoxin; Drug Interactions; Humans; Kidney Failure, Chronic; Renal Dialysis; Verapamil

1990
Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat.
    Journal of cardiovascular pharmacology, 1987, Volume: 10 Suppl 10

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Diabetes Mellitus, Expe

1987
Calcium channel blockade in dialysis patients with left ventricular hypertrophy and well-preserved systolic function.
    Journal of cardiovascular pharmacology, 1987, Volume: 10 Suppl 10

    Topics: Aged; Blood Pressure; Body Weight; Cardiomegaly; Cardiomyopathy, Dilated; Echocardiography; Female;

1987
Correction of glucose intolerance and the impaired insulin release of chronic renal failure by verapamil.
    Kidney international, 1989, Volume: 36, Issue:5

    Topics: Animals; Calcium Channels; Glucose; Hyperparathyroidism, Secondary; Insulin; Insulin Secretion; Isle

1989
The effect of calcium antagonists on the peritoneal membrane in patients on CAPD.
    Advances in peritoneal dialysis. Conference on Peritoneal Dialysis, 1989, Volume: 5

    Topics: Adult; Aged; Calcium; Creatinine; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Perito

1989
Effects of verapamil on the abnormalities in fatty acid oxidation of myocardium.
    Kidney international, 1989, Volume: 36, Issue:3

    Topics: Animals; Carnitine O-Palmitoyltransferase; Fatty Acids; Kidney Failure, Chronic; Male; Mitochondria,

1989
Effect of verapamil on chemiluminescence of peripheral blood neutrophils during hemodialysis in chronic uremic patients.
    Archivum immunologiae et therapiae experimentalis, 1989, Volume: 37, Issue:1-2

    Topics: Adult; Cell Count; Cell Division; Chronic Disease; Female; Free Radicals; Humans; Kidney Failure, Ch

1989
Parathyroid hormone interferes with extrarenal disposition of potassium in chronic renal failure.
    Nephron, 1989, Volume: 52, Issue:3

    Topics: Animals; Extracellular Space; Hyperparathyroidism; Kidney Failure, Chronic; Parathyroid Hormone; Pot

1989
Effect of verapamil on bone resorption and formation in uremic rats.
    Mineral and electrolyte metabolism, 1989, Volume: 15, Issue:5

    Topics: Animals; Bone and Bones; Bone Resorption; Calcium; Creatinine; Hyperparathyroidism; Kidney Failure,

1989
"Intact nephrons" as the primary origin of proteinuria in chronic renal disease. Study in the rat model of subtotal nephrectomy.
    The Journal of clinical investigation, 1988, Volume: 82, Issue:5

    Topics: Animals; Glomerular Filtration Rate; Hemodynamics; Kidney Failure, Chronic; Kidney Glomerulus; Nephr

1988
Verapamil reverses PTH- or CRF-induced abnormal fatty acid oxidation in muscle.
    Kidney international, 1988, Volume: 34, Issue:6

    Topics: Animals; Calcium Radioisotopes; Carnitine O-Palmitoyltransferase; Fatty Acids; Kidney Failure, Chron

1988
An evaluation of the pharmacokinetics, pharmacodynamics, and dialyzability of verapamil in chronic hemodialysis patients.
    Journal of clinical pharmacology, 1988, Volume: 28, Issue:9

    Topics: Adult; Aged; Female; Half-Life; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis;

1988
Cyclosporin-verapamil interaction.
    British journal of clinical pharmacology, 1988, Volume: 25, Issue:3

    Topics: Adult; Creatinine; Cyclosporins; Drug Interactions; Humans; Kidney Failure, Chronic; Kidney Transpla

1988
Remnant kidney hypermetabolism and progression of chronic renal failure.
    The American journal of physiology, 1988, Volume: 254, Issue:2 Pt 2

    Topics: Animals; Disease Models, Animal; Kidney; Kidney Failure, Chronic; Male; Oxygen Consumption; Perfusio

1988
The use of calcium antagonists in patients with renal failure.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1987, Volume: 5, Issue:4

    Topics: Calcium Channel Blockers; Diltiazem; Humans; Kidney Failure, Chronic; Nifedipine; Nitrendipine; Vera

1987
Verapamil protects against progression of experimental chronic renal failure.
    Kidney international, 1987, Volume: 31, Issue:1

    Topics: Animals; Blood Pressure; Kidney; Kidney Failure, Chronic; Male; Nephrectomy; Rats; Rats, Inbred Stra

1987
Verapamil improves defective duodenal calcium absorption in experimental chronic renal failure.
    Mineral and electrolyte metabolism, 1986, Volume: 12, Issue:5-6

    Topics: Aminoquinolines; Animals; Calcium; Duodenum; Hypoxia; Intestinal Absorption; Kidney Cortex; Kidney F

1986
Pharmacokinetics of verapamil in patients with renal failure.
    European journal of clinical pharmacology, 1985, Volume: 28, Issue:4

    Topics: Administration, Oral; Adult; Aged; Female; Humans; Injections, Intravenous; Kidney Failure, Chronic;

1985
Verapamil kinetics during maintenance hemodialysis.
    American journal of nephrology, 1985, Volume: 5, Issue:5

    Topics: Administration, Oral; Half-Life; Humans; Kidney Failure, Chronic; Kinetics; Male; Middle Aged; Renal

1985
[Management of ventricular tachycardias using Isoptin].
    Medizinische Klinik, 1968, May-03, Volume: 63, Issue:18

    Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Hyperkalemia; Inject

1968